ReviewJournal of asthma and allergy2015
Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases.
Review in Journal of asthma and allergy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 54 citations in OpenAlex.
- Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.The Journal of allergy and clinical immunology · 2020Trial
- The Pharmacokinetics and Relative Bioavailability of Mepolizumab 100 mg Liquid Formulation Administered Subcutaneously to Healthy Participants: A Randomized Trial.Clinical pharmacology in drug development · 2020Trial
- Eosinophilic Granulomatosis with Polyangiitis that Manifested after Administration of Benralizumab in a Patient with Refractory Recurrent Bronchial Asthma.Internal medicine (Tokyo, Japan) · 2026Article
- The Importance of Lung Innate Immunity During Health and Disease.Pathogens (Basel, Switzerland) · 2025Review
- Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders.Biomedicines · 2023Article
- β-Arrestin-biased proteinase-activated receptor-2 antagonist C781 limits allergen-induced airway hyperresponsiveness and inflammation.British journal of pharmacology · 2023Article
- From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.Allergy · 2022Review
- Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET.ERJ open research · 2022Article
- Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis.The European respiratory journal · 2020Observational
- Immunologic Adverse Effects of Biologics for the Treatment of Atopy.Clinical reviews in allergy & immunology · 2020Review
- Response to mepolizumab treatment is sustained across 4-weekly dosing periods.ERJ open research · 2020Article
- Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme.The European respiratory journal · 2020Observational
- Nasal mucus proteome and its involvement in allergic rhinitis.Expert review of proteomics · 2020Article
- IgE autoantibodies and autoreactive T cells and their role in children and adults with atopic dermatitis.Clinical and translational allergy · 2020Review
- Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs.Journal of asthma and allergy · 2020Article
- New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic.Biologics : targets & therapy · 2019Article
- Aspirin-exacerbated respiratory disease and current treatment modalities.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2017Review
- Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.Drug design, development and therapy · 2017Review
- Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma.Frontiers in medicine · 2017Review
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a complex disorder frequently associated with a poor symptom control, concomitant morbidity, mortality, and significant health care costs due to lack of compliance or inadequate therapeutic options. Interleukin-5 (IL-5) plays a key role in the pathogenesis of eosinophilic disorders, and in the latest years has become a definite target for treatment. Besides asthma, other hypereosinophilic disorders include the hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis, sinonasal polyposis, COPD with eosinophilic airway inflammation, allergic rhinitis, atopic dermatitis, eosinophilic esophagitis. The introduction of mepolizumab, a fully humanized monoclonal antibody that binds to IL-5, may represent a useful therapeutic option to control exacerbations and improve asthma-related quality of life in a subgroup of patients with persistent airway eosinophilia and moderate to severe asthma. Several studies carried out in recent years allow, at present, a careful patient selection for appropriate individualized treatment in severe asthma. Further research is anyway needed in order to better understand the pathogenetic mechanisms of asthma and to find new biomarkers. The high costs of biological agents as compared with standard drugs may be largely offset by increased clinical efficacy and good safety profile in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.